<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <BookBackmatter>
      <BookBackmatterInfo>
        <BookBackmatterFirstPage>419</BookBackmatterFirstPage>
        <BookBackmatterLastPage>428</BookBackmatterLastPage>
      </BookBackmatterInfo>
      <BodyBackmatter>
        <Index ID="Ind1">
          <Heading>Index</Heading>
          <IndexDiv>
            <Heading>A</Heading>
            <IndexEntry>
              <PrimaryIE>Abiraterone acetate</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                ABT-627.
                <Emphasis Type="Italic">See</Emphasis>
                Atrasentan
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                Active cellular immunotherapy.
                <Emphasis Type="Italic">See</Emphasis>
                Sipuleucel-T vaccine, CRPC
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Acute myelogenous leukemia (AML), mitoxantrone</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                ADAM.
                <Emphasis Type="Italic">See</Emphasis>
                Androgen deficiency of aging male
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Adrenal androgen synthesis inhibitor therapies</PrimaryIE>
              <SecondaryIE>abiraterone acetate</SecondaryIE>
              <SecondaryIE>adrenalectomy</SecondaryIE>
              <SecondaryIE>aminoglutethimide</SecondaryIE>
              <SecondaryIE>anti-androgens and anti-androgen-withdrawal</SecondaryIE>
              <SecondaryIE>corticosteroids</SecondaryIE>
              <SecondaryIE>CYP17 inhibitors</SecondaryIE>
              <SecondaryIE>estrogens</SecondaryIE>
              <SecondaryIE>ketoconazole</SecondaryIE>
              <SecondaryIE>orchiectomy and GnRH/LHRH analogs</SecondaryIE>
              <SecondaryIE>progestins</SecondaryIE>
              <SecondaryIE>progressive disease mechanisms</SecondaryIE>
              <SecondaryIE>role of androgens</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Adrenalectomy</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Agonists, LHRH-I</PrimaryIE>
              <SecondaryIE>principles of oncological and gynecological use</SecondaryIE>
              <SecondaryIE>prostate cancer therapy</SecondaryIE>
              <SecondaryIE>sustained delivery systems</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Akt pathways</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>5-Alpha reductase</PrimaryIE>
              <SecondaryIE>androgenic steroids</SecondaryIE>
              <SecondaryIE>androgen metabolic pathway</SecondaryIE>
              <SecondaryIE>androgens and androgen receptor</SecondaryIE>
              <SecondaryIE>antiandrogens</SecondaryIE>
              <SecondaryIE>and cancer</SecondaryIE>
              <SecondaryIE>clinical studies</SecondaryIE>
              <TertiaryIE>finasteride treatment</TertiaryIE>
              <TertiaryIE>prostate cancer prevention trial (PCPT) study</TertiaryIE>
              <TertiaryIE>
                <Emphasis Type="Italic">serenoa repens</Emphasis>
              </TertiaryIE>
              <SecondaryIE>inhibitors</SecondaryIE>
              <SecondaryIE>role in non-malignant disease</SecondaryIE>
              <SecondaryIE>testosterone to dihydrotestosterone conversion</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Aminoglutethimide</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Androgen deficiency of aging male (ADAM)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Androgen deprivation therapy (ADT)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Androgen receptor antagonists</PrimaryIE>
              <SecondaryIE>BMS 641988</SecondaryIE>
              <SecondaryIE>clinical applications</SecondaryIE>
              <TertiaryIE>antagonist withdrawal responses</TertiaryIE>
              <TertiaryIE>combined castration and AR antagonist therapy</TertiaryIE>
              <TertiaryIE>in CRPC</TertiaryIE>
              <TertiaryIE>monotherapy in previously untreated patients</TertiaryIE>
              <SecondaryIE>MDV3100</SecondaryIE>
              <SecondaryIE>mechanisms of action</SecondaryIE>
              <TertiaryIE>AR activation by agonist binding</TertiaryIE>
              <TertiaryIE>role of transcriptional corepressors</TertiaryIE>
              <TertiaryIE>structural changes, antagonist binding</TertiaryIE>
              <SecondaryIE>monotherapy</SecondaryIE>
              <SecondaryIE>reactivation and resistance mechanism</SecondaryIE>
              <TertiaryIE>expression of antagonist activated mutant ARs</TertiaryIE>
              <TertiaryIE>increased AR expression</TertiaryIE>
              <TertiaryIE>increased intratumoral androgen synthesis</TertiaryIE>
              <TertiaryIE>kinase signaling pathways</TertiaryIE>
              <TertiaryIE>
                transcriptional coactivator
                <Emphasis Type="Italic">vs</Emphasis>
                . corepressor proteins
              </TertiaryIE>
              <SecondaryIE>steroidal and nonsteroidal</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Androgen receptors (AR)</PrimaryIE>
              <SecondaryIE>5 alpha reductase</SecondaryIE>
              <SecondaryIE>androgen synthesis, inhibitors</SecondaryIE>
              <SecondaryIE>
                antagonists (
                <Emphasis Type="Italic">see also</Emphasis>
                Androgen receptor antagonists)
              </SecondaryIE>
              <SecondaryIE>biology</SecondaryIE>
              <TertiaryIE>coregulators</TertiaryIE>
              <TertiaryIE>gene amplification</TertiaryIE>
              <TertiaryIE>ligand availability</TertiaryIE>
              <TertiaryIE>mutations</TertiaryIE>
              <TertiaryIE>posttranslational modification</TertiaryIE>
              <TertiaryIE>role</TertiaryIE>
              <TertiaryIE>structure</TertiaryIE>
              <SecondaryIE>castration-resistant disease</SecondaryIE>
              <SecondaryIE>chaperone inhibitors</SecondaryIE>
              <SecondaryIE>genes and polymorphisms</SecondaryIE>
              <SecondaryIE>intracrine de novo synthesis of testosterone</SecondaryIE>
              <SecondaryIE>mechanism of action</SecondaryIE>
              <TertiaryIE>AR-associated coregulators</TertiaryIE>
              <TertiaryIE>dihydrotestosterone (DHT)</TertiaryIE>
              <TertiaryIE>gene expression regulation</TertiaryIE>
              <SecondaryIE>reactivation</SecondaryIE>
              <SecondaryIE>structure and function</SecondaryIE>
              <TertiaryIE>DNA-binding domain (DBD)</TertiaryIE>
              <TertiaryIE>ligand-binding domain (LBD)</TertiaryIE>
              <TertiaryIE>N-terminal domain (NTD)</TertiaryIE>
              <SecondaryIE>synthesis and metabolites</SecondaryIE>
              <SecondaryIE>therapeutic potential, signaling pathways</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Androgens</PrimaryIE>
              <SecondaryIE>action on prostate</SecondaryIE>
              <SecondaryIE>biosynthesis</SecondaryIE>
              <SecondaryIE>intratumoral synthesis</SecondaryIE>
              <SecondaryIE>metabolic pathways</SecondaryIE>
              <TertiaryIE>androgen receptor</TertiaryIE>
              <TertiaryIE>aromatase (CYP19A1)</TertiaryIE>
              <TertiaryIE>biosynthesis and metabolism</TertiaryIE>
              <TertiaryIE>cytochrome P450 17</TertiaryIE>
              <TertiaryIE>dihydrotestosterone</TertiaryIE>
              <TertiaryIE>finasteride and dutasteride effects</TertiaryIE>
              <TertiaryIE>gene fusions</TertiaryIE>
              <TertiaryIE>HSD17 gene</TertiaryIE>
              <TertiaryIE>3β-hydroxysteroid dehydrogenase</TertiaryIE>
              <TertiaryIE>organic anion transporter OATP1B3</TertiaryIE>
              <TertiaryIE>pharmacogenetics</TertiaryIE>
              <TertiaryIE>prevention</TertiaryIE>
              <TertiaryIE>steroid 5α-reductase</TertiaryIE>
              <TertiaryIE>treatment</TertiaryIE>
              <SecondaryIE>and prostate cancer</SecondaryIE>
              <SecondaryIE>testosterone replacement therapy</SecondaryIE>
              <TertiaryIE>follow up for prostate cancer</TertiaryIE>
              <TertiaryIE>risk of prostate cancer</TertiaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Andropause</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Angiogenesis</PrimaryIE>
              <SecondaryIE>antiangiogenic agents in</SecondaryIE>
              <SecondaryIE>bevacizumab, targeting of</SecondaryIE>
              <SecondaryIE>bFGF</SecondaryIE>
              <SecondaryIE>classification of</SecondaryIE>
              <TertiaryIE>direct inhibitors of</TertiaryIE>
              <TertiaryIE>exclusive/inclusive</TertiaryIE>
              <TertiaryIE>indirect inhibitors of</TertiaryIE>
              <SecondaryIE>combination therapies</SecondaryIE>
              <SecondaryIE>endogenous inhibitors of</SecondaryIE>
              <SecondaryIE>HIF in</SecondaryIE>
              <SecondaryIE>and invasiveness, antineoplastic activity</SecondaryIE>
              <SecondaryIE>investigational inhibitors</SecondaryIE>
              <TertiaryIE>cytokines</TertiaryIE>
              <TertiaryIE>5,6-dimethylxanthenone acetic acid (DMXAA)</TertiaryIE>
              <TertiaryIE>integrins</TertiaryIE>
              <TertiaryIE>tyrosine kinases</TertiaryIE>
              <TertiaryIE>VEGF and VEGF-receptor (VEGF-R) family</TertiaryIE>
              <SecondaryIE>MVD and VEGF</SecondaryIE>
              <SecondaryIE>pharmacogenetics of</SecondaryIE>
              <TertiaryIE>antiangiogenic therapy</TertiaryIE>
              <TertiaryIE>bevacizumab and thalidomide</TertiaryIE>
              <TertiaryIE>endostatin gene</TertiaryIE>
              <TertiaryIE>HIF-1α gene</TertiaryIE>
              <TertiaryIE>metalloproteinase-1 (MMP1) gene</TertiaryIE>
              <TertiaryIE>PDGF and PDGFR gene</TertiaryIE>
              <TertiaryIE>tumor necrosis factor (TNF) gene</TertiaryIE>
              <TertiaryIE>VEGF gene</TertiaryIE>
              <TertiaryIE>VEGFR2</TertiaryIE>
              <SecondaryIE>rationale for</SecondaryIE>
              <SecondaryIE>resistance to</SecondaryIE>
              <SecondaryIE>role of</SecondaryIE>
              <SecondaryIE>surrogate markers of</SecondaryIE>
              <SecondaryIE>switch and regulatory proteins</SecondaryIE>
              <TertiaryIE>endothelial cells (ECs) in</TertiaryIE>
              <TertiaryIE>proangiogenic factors</TertiaryIE>
              <SecondaryIE>VEGF, regulation of</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Antagonistic analogs, LHRH-I</PrimaryIE>
              <SecondaryIE>clinical applications</SecondaryIE>
              <SecondaryIE>clinical findings</SecondaryIE>
              <SecondaryIE>cytotoxic analogs, in prostate cancer</SecondaryIE>
              <SecondaryIE>degarelix</SecondaryIE>
              <SecondaryIE>development</SecondaryIE>
              <SecondaryIE>direct effects on tumors</SecondaryIE>
              <SecondaryIE>edematogenic effect</SecondaryIE>
              <SecondaryIE>gynecological and oncological use, effects on pituitary receptors</SecondaryIE>
              <SecondaryIE>mechanism of action</SecondaryIE>
              <SecondaryIE>receptors</SecondaryIE>
              <SecondaryIE>side effects</SecondaryIE>
              <SecondaryIE>targeted cytotoxic</SecondaryIE>
              <SecondaryIE>use in BPH</SecondaryIE>
              <SecondaryIE>use in prostate cancer</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Anti-angiogenesis agents</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                Anti-CTLA-4 immunotherapy, prostate cancer.
                <Emphasis Type="Italic">See also</Emphasis>
                Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Antineoplastic activity, vitamin D</PrimaryIE>
              <SecondaryIE>angiogenesis and invasiveness</SecondaryIE>
              <SecondaryIE>apoptosis</SecondaryIE>
              <SecondaryIE>proliferation</SecondaryIE>
              <SecondaryIE>signaling</SecondaryIE>
              <SecondaryIE>spectrum of activity</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                APC8015.
                <Emphasis Type="Italic">See</Emphasis>
                Sipuleucel-T vaccine, CRPC
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Apoptosis</PrimaryIE>
              <SecondaryIE>antineoplastic activity</SecondaryIE>
              <SecondaryIE>
                <Emphasis Type="Italic">bcl-2</Emphasis>
                gene
              </SecondaryIE>
              <SecondaryIE>CLU</SecondaryIE>
              <SecondaryIE>endothelin-1 (ET-1)</SecondaryIE>
              <SecondaryIE>extrinsic and instrinsic pathways</SecondaryIE>
              <SecondaryIE>Fas-induced death</SecondaryIE>
              <SecondaryIE>Hsp27</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                AR.
                <Emphasis Type="Italic">See</Emphasis>
                Androgen receptors
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Aromatase enzyme</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Atrasentan</PrimaryIE>
              <SecondaryIE>phase III trials in</SecondaryIE>
              <TertiaryIE>disease progression time in</TertiaryIE>
              <TertiaryIE>M00-211</TertiaryIE>
              <TertiaryIE>M00-244</TertiaryIE>
              <TertiaryIE>Southwestern Oncology Group (SWOG)</TertiaryIE>
              <SecondaryIE>phase II trials in</SecondaryIE>
              <TertiaryIE>M96-500</TertiaryIE>
              <TertiaryIE>M96-594</TertiaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>B</Heading>
            <IndexEntry>
              <PrimaryIE>Basic fibroblast growth factor (bFGF)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                <Emphasis Type="Italic">Bcl-2</Emphasis>
                gene
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Benign prostatic hyperplasia (BPH)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Bevacizumab</PrimaryIE>
              <SecondaryIE>angiogenesis pathway targeting</SecondaryIE>
              <SecondaryIE>clinical role of</SecondaryIE>
              <TertiaryIE>castrate resistant prostate cancer</TertiaryIE>
              <TertiaryIE>castrate sensitive prostate cancer</TertiaryIE>
              <TertiaryIE>preclinical data</TertiaryIE>
              <TertiaryIE>success of</TertiaryIE>
              <SecondaryIE>VEGF</SecondaryIE>
              <TertiaryIE>angiogenesis regulation</TertiaryIE>
              <TertiaryIE>targeted inhibition</TertiaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Bicalutamide</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Biomarkers</PrimaryIE>
              <SecondaryIE>biochemical markers</SecondaryIE>
              <SecondaryIE>blood-based</SecondaryIE>
              <SecondaryIE>cancer</SecondaryIE>
              <SecondaryIE>circulating tumor cells</SecondaryIE>
              <SecondaryIE>prostate specific antigen</SecondaryIE>
              <SecondaryIE>tissue-based</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Bisphosphonates, bone metastases</PrimaryIE>
              <SecondaryIE>in androgen sensitive prostate cancer</SecondaryIE>
              <SecondaryIE>in castration-resistant prostate cancer</SecondaryIE>
              <TertiaryIE>randomized controlled trials</TertiaryIE>
              <TertiaryIE>skeletal-related events</TertiaryIE>
              <TertiaryIE>zoledronic acid</TertiaryIE>
              <SecondaryIE>denosumab</SecondaryIE>
              <SecondaryIE>osteoporosis and fractures prevention, ADT</SecondaryIE>
              <SecondaryIE>prevention of</SecondaryIE>
              <SecondaryIE>safety</SecondaryIE>
              <TertiaryIE>osteonecrosis of jaw (ONJ)</TertiaryIE>
              <TertiaryIE>renal toxicity</TertiaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Blood-based protein biomarkers</PrimaryIE>
              <SecondaryIE>bone markers</SecondaryIE>
              <SecondaryIE>prostate specific antigen (PSA)</SecondaryIE>
              <SecondaryIE>protein identiifcation and quantification</SecondaryIE>
              <SecondaryIE>protein/peptide separation</SecondaryIE>
              <SecondaryIE>proteomic technologies</SecondaryIE>
              <SecondaryIE>sample preparation</SecondaryIE>
              <SecondaryIE>subproteomes</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Bone</PrimaryIE>
              <SecondaryIE>biology of</SecondaryIE>
              <TertiaryIE>anatomy</TertiaryIE>
              <TertiaryIE>cathepsin K and acid secretion</TertiaryIE>
              <TertiaryIE>components in</TertiaryIE>
              <TertiaryIE>domains</TertiaryIE>
              <TertiaryIE>OPG</TertiaryIE>
              <TertiaryIE>RANKL</TertiaryIE>
              <SecondaryIE>genes</SecondaryIE>
              <SecondaryIE>osteoblastic metastases</SecondaryIE>
              <SecondaryIE>osteoclastic metastases</SecondaryIE>
              <TertiaryIE>interleukin-6 (IL-6)</TertiaryIE>
              <TertiaryIE>matrix metalloproteinases (MMPs)</TertiaryIE>
              <TertiaryIE>PTHrP protein</TertiaryIE>
              <TertiaryIE>RANKL and OPG</TertiaryIE>
              <SecondaryIE>osteogenic factors</SecondaryIE>
              <SecondaryIE>physiology</SecondaryIE>
              <SecondaryIE>prostate carcinoma cells and</SecondaryIE>
              <SecondaryIE>remodeling</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Bone metastases</PrimaryIE>
              <SecondaryIE>clinical manifestations of</SecondaryIE>
              <TertiaryIE>hypercalcemia and anemia</TertiaryIE>
              <TertiaryIE>pain</TertiaryIE>
              <SecondaryIE>c-Met</SecondaryIE>
              <SecondaryIE>endothelin axis and</SecondaryIE>
              <TertiaryIE>osteoblasts</TertiaryIE>
              <TertiaryIE>vicious cycle hypothesis</TertiaryIE>
              <SecondaryIE>endothelins (ETs)</SecondaryIE>
              <SecondaryIE>osteoblastic, pathophysiology of</SecondaryIE>
              <SecondaryIE>targeted therapies</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Bortezomib</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Brachytherapy</PrimaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>C</Heading>
            <IndexEntry>
              <PrimaryIE>Cabazitaxel</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Calcitriol</PrimaryIE>
              <SecondaryIE>combination therapy</SecondaryIE>
              <SecondaryIE>and vitamin D analogs</SecondaryIE>
              <TertiaryIE>antineoplastic agents</TertiaryIE>
              <TertiaryIE>phase II studies</TertiaryIE>
              <TertiaryIE>phase I studies</TertiaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Cancer biomarkers</PrimaryIE>
              <SecondaryIE>classification of</SecondaryIE>
              <SecondaryIE>predictive</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Carboplatin</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Caspase-8</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Castrate sensitive prostate cancer</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Castration-AR antagonist therapy</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Castration-resistant prostate cancer (CPRC)</PrimaryIE>
              <SecondaryIE>
                adrenal androgen synthesis inhibitor therapies (
                <Emphasis Type="Italic">see also</Emphasis>
                Adrenal androgen synthesis inhibitor therapies)
              </SecondaryIE>
              <SecondaryIE>androgen receptor</SecondaryIE>
              <TertiaryIE>antagonists in</TertiaryIE>
              <TertiaryIE>gene amplification</TertiaryIE>
              <TertiaryIE>mutations</TertiaryIE>
              <TertiaryIE>posttranslational modification of</TertiaryIE>
              <TertiaryIE>signaling axis</TertiaryIE>
              <TertiaryIE>transactivation</TertiaryIE>
              <SecondaryIE>bevacizumab</SecondaryIE>
              <TertiaryIE>CALGB 90401 treatment schema</TertiaryIE>
              <TertiaryIE>clinical trials of</TertiaryIE>
              <TertiaryIE>combinational studies</TertiaryIE>
              <SecondaryIE>clinical endpoint</SecondaryIE>
              <TertiaryIE>circulating tumor cells</TertiaryIE>
              <TertiaryIE>phase III trials</TertiaryIE>
              <TertiaryIE>PSA based end-points</TertiaryIE>
              <SecondaryIE>combination chemotherapy</SecondaryIE>
              <SecondaryIE>CTLA-4 blockade</SecondaryIE>
              <SecondaryIE>definition</SecondaryIE>
              <SecondaryIE>docetaxel</SecondaryIE>
              <SecondaryIE>
                endothelin receptors (
                <Emphasis Type="Italic">see</Emphasis>
                Endothelin-1 receptors, CRPC)
              </SecondaryIE>
              <SecondaryIE>epothilones in</SecondaryIE>
              <TertiaryIE>ixabepilone</TertiaryIE>
              <TertiaryIE>patupilone</TertiaryIE>
              <TertiaryIE>phase I clinical trials of</TertiaryIE>
              <TertiaryIE>phase II clinical trials of</TertiaryIE>
              <TertiaryIE>pre-clinical data</TertiaryIE>
              <SecondaryIE>GVAX</SecondaryIE>
              <SecondaryIE>and IGFBPs</SecondaryIE>
              <SecondaryIE>ligand availability</SecondaryIE>
              <SecondaryIE>mitoxantrone</SecondaryIE>
              <SecondaryIE>molecular mechanisms</SecondaryIE>
              <SecondaryIE>natural history</SecondaryIE>
              <SecondaryIE>ONY-P1</SecondaryIE>
              <SecondaryIE>
                platinum agents (
                <Emphasis Type="Italic">see</Emphasis>
                Platinum agents)
              </SecondaryIE>
              <SecondaryIE>poxviral vaccine</SecondaryIE>
              <SecondaryIE>PSA-TRICOM</SecondaryIE>
              <SecondaryIE>sequential chemotherapy</SecondaryIE>
              <SecondaryIE>sipuleucel-T</SecondaryIE>
              <TertiaryIE>clinical efficacy</TertiaryIE>
              <TertiaryIE>Kaplan–Meier survival benefit</TertiaryIE>
              <TertiaryIE>PA2024, recombinant prostate antigen protein</TertiaryIE>
              <TertiaryIE>safety and tolerability</TertiaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Cathepsin K</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Cediranib</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Celecoxib trial</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Cell biology</PrimaryIE>
              <SecondaryIE>androgen deprivation therapy (ADT)</SecondaryIE>
              <SecondaryIE>androgen receptor (AR)</SecondaryIE>
              <TertiaryIE>androgen synthesis, inhibitors</TertiaryIE>
              <TertiaryIE>antagonists</TertiaryIE>
              <TertiaryIE>chaperone inhibitors</TertiaryIE>
              <TertiaryIE>intracrine de novo synthesis of testosterone</TertiaryIE>
              <TertiaryIE>reactivation</TertiaryIE>
              <TertiaryIE>transcriptional genomic action</TertiaryIE>
              <SecondaryIE>angiogenesis</SecondaryIE>
              <SecondaryIE>apoptotic regulation</SecondaryIE>
              <TertiaryIE>bcl-2 gene</TertiaryIE>
              <TertiaryIE>CLU</TertiaryIE>
              <TertiaryIE>extrinsic and instrinsic pathways</TertiaryIE>
              <TertiaryIE>Fas-induced death</TertiaryIE>
              <TertiaryIE>Hsp27</TertiaryIE>
              <SecondaryIE>bone metastases</SecondaryIE>
              <TertiaryIE>c-Met</TertiaryIE>
              <TertiaryIE>endothelins (ETs)</TertiaryIE>
              <TertiaryIE>osteoclastic bone resorption</TertiaryIE>
              <TertiaryIE>Src inhibitors</TertiaryIE>
              <SecondaryIE>bone-predominant metastatic progression</SecondaryIE>
              <SecondaryIE>cell proliferation and survival</SecondaryIE>
              <SecondaryIE>inflammation</SecondaryIE>
              <TertiaryIE>associated proteins</TertiaryIE>
              <TertiaryIE>hedgehog pathway</TertiaryIE>
              <TertiaryIE>nuclear transcription factor (NFκB)</TertiaryIE>
              <TertiaryIE>stroma-derived factor (SDF-1/CXCL12)</TertiaryIE>
              <SecondaryIE>molecular mechanisms</SecondaryIE>
              <SecondaryIE>signal transduction pathways</SecondaryIE>
              <TertiaryIE>IGF and IGF-1R</TertiaryIE>
              <TertiaryIE>IGFBPs and CRPC</TertiaryIE>
              <TertiaryIE>PI3K-mediated survival signaling</TertiaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Cetrorelix</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Chemoprevention strategy</PrimaryIE>
              <SecondaryIE>active surveillance cohort</SecondaryIE>
              <SecondaryIE>celecoxib trial</SecondaryIE>
              <SecondaryIE>clinical trials</SecondaryIE>
              <SecondaryIE>elevated PSA, negative biopsy cohort</SecondaryIE>
              <SecondaryIE>exisulind effect</SecondaryIE>
              <SecondaryIE>high-grade prostatic intraepithelial neoplasia (HGPIN) cohort</SecondaryIE>
              <SecondaryIE>α(alpha)-hydroxyvitamin D2 trial</SecondaryIE>
              <SecondaryIE>PCPT</SecondaryIE>
              <SecondaryIE>positive family history cohort</SecondaryIE>
              <SecondaryIE>pre-prostatectomy cohort</SecondaryIE>
              <SecondaryIE>REDUCE</SecondaryIE>
              <SecondaryIE>SELECT</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Chromogranin A (CgA)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Circulating tumor cells (CTC), biomarker</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Cisplatin</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Clusterin isoform 2 (sCLU-2)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>c-Met</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Colchicine class</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Combination chemotherapy</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Combined androgen blockade (CAB)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Combretastatin A-4</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Congestive heart failure (CHF), mitoxantrone</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Corticosteroids</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Cyclooxygenase-2, inflammation</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Cytochrome P450 17 (CYP17)</PrimaryIE>
              <SecondaryIE>abiraterone acetate</SecondaryIE>
              <SecondaryIE>TAK-700 and TOK-001</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Cytochrome P450 19A1 (CYP19A1) gene</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Cytokines</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Cytotoxic drugs</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade</PrimaryIE>
              <SecondaryIE>clinical evaluation</SecondaryIE>
              <SecondaryIE>combination therapy</SecondaryIE>
              <TertiaryIE>GM-CSF</TertiaryIE>
              <TertiaryIE>ipilimumab</TertiaryIE>
              <TertiaryIE>radiotherapy</TertiaryIE>
              <SecondaryIE>preclinical models</SecondaryIE>
              <SecondaryIE>regulatory T cells (Tregs)</SecondaryIE>
              <SecondaryIE>T cell activation, mechanism</SecondaryIE>
              <SecondaryIE>toxicity</SecondaryIE>
              <SecondaryIE>vaccination</SecondaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>D</Heading>
            <IndexEntry>
              <PrimaryIE>Degarelix</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Denosumab</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                DHT.
                <Emphasis Type="Italic">See</Emphasis>
                Dihydrotestosterone
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Dietary risk factors</PrimaryIE>
              <SecondaryIE>biological mechanisms, meat and poultry</SecondaryIE>
              <SecondaryIE>cruciferous vegetables</SecondaryIE>
              <SecondaryIE>fish and marine omega-3 fatty acids</SecondaryIE>
              <SecondaryIE>fruits</SecondaryIE>
              <SecondaryIE>incidence</SecondaryIE>
              <SecondaryIE>legumes</SecondaryIE>
              <SecondaryIE>lycopene</SecondaryIE>
              <SecondaryIE>meat, poultry, and fat</SecondaryIE>
              <SecondaryIE>milk, dairy, &amp; calcium</SecondaryIE>
              <SecondaryIE>poultry</SecondaryIE>
              <SecondaryIE>red and processed meat</SecondaryIE>
              <SecondaryIE>selenium</SecondaryIE>
              <SecondaryIE>soy</SecondaryIE>
              <SecondaryIE>tomatoes</SecondaryIE>
              <SecondaryIE>vegetables</SecondaryIE>
              <SecondaryIE>vitamin E</SecondaryIE>
              <SecondaryIE>WCRF-AICR report</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Diethylstilbestrol (DES)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Dihydrotestosterone (DHT)</PrimaryIE>
              <SecondaryIE>action on prostate</SecondaryIE>
              <SecondaryIE>biosynthesis</SecondaryIE>
              <SecondaryIE>homeostasis</SecondaryIE>
              <SecondaryIE>metabolic pathways</SecondaryIE>
              <SecondaryIE>structure of</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                Dihydroxyanthracenedione (DHAD).
                <Emphasis Type="Italic">See</Emphasis>
                Mitoxantrone
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>DNA-binding domain (DBD)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Docetaxel</PrimaryIE>
              <SecondaryIE>clinical endpoints</SecondaryIE>
              <SecondaryIE>clinical implications, SWOG 99-16 and TAX 327</SecondaryIE>
              <SecondaryIE>CYP3A enzymes</SecondaryIE>
              <SecondaryIE>distribution of</SecondaryIE>
              <SecondaryIE>FDA approval</SecondaryIE>
              <SecondaryIE>mechanism of action</SecondaryIE>
              <SecondaryIE>metabolic and transport pathway</SecondaryIE>
              <SecondaryIE>optimal timing of chemotherapy</SecondaryIE>
              <SecondaryIE>pharmacogenetics</SecondaryIE>
              <TertiaryIE>ABCB1</TertiaryIE>
              <TertiaryIE>ABCG2 and SLCO1B3</TertiaryIE>
              <TertiaryIE>CYP3A4 and CYP3A5</TertiaryIE>
              <TertiaryIE>CYP1B1</TertiaryIE>
              <SecondaryIE>prostate cancer</SecondaryIE>
              <SecondaryIE>and prostatectomy</SecondaryIE>
              <SecondaryIE>prostate-specific antigen (PSA) screening</SecondaryIE>
              <SecondaryIE>and radiation therapy</SecondaryIE>
              <SecondaryIE>SWOG 99-16</SecondaryIE>
              <TertiaryIE>
                docetaxel-estramustine (DE)
                <Emphasis Type="Italic">vs</Emphasis>
                . mitoxantrone-prednisone (MP)
              </TertiaryIE>
              <TertiaryIE>quality of life and pain scores</TertiaryIE>
              <SecondaryIE>TAX 327</SecondaryIE>
              <SecondaryIE>taxane-based therapy</SecondaryIE>
              <SecondaryIE>taxane-combination therapy</SecondaryIE>
              <TertiaryIE>anti-angiogenesis agents</TertiaryIE>
              <TertiaryIE>bone targeted therapies</TertiaryIE>
              <TertiaryIE>calcitriol combination therapy</TertiaryIE>
              <TertiaryIE>vaccine-taxane therapy</TertiaryIE>
              <SecondaryIE>variability, non-genetic sources of</SecondaryIE>
              <TertiaryIE>age</TertiaryIE>
              <TertiaryIE>alpha1-acid glycoprotein (AAG)</TertiaryIE>
              <TertiaryIE>clearance, inter-individual variation</TertiaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Dolastatin peptides</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Drug development</PrimaryIE>
              <SecondaryIE>clinical endpoint</SecondaryIE>
              <TertiaryIE>biomarkers</TertiaryIE>
              <TertiaryIE>phase III setting</TertiaryIE>
              <TertiaryIE>phase II setting</TertiaryIE>
              <SecondaryIE>FDA approved treatments</SecondaryIE>
              <TertiaryIE>approval process</TertiaryIE>
              <TertiaryIE>challenges</TertiaryIE>
              <TertiaryIE>cytotoxic agents</TertiaryIE>
              <TertiaryIE>hormonal agents</TertiaryIE>
              <TertiaryIE>supportive agents</TertiaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Drug interactions, mitoxantrone</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Dutasteride</PrimaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>E</Heading>
            <IndexEntry>
              <PrimaryIE>Electrospray ionization (ESI)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Endogenous inhibitors, angiogenesis</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Endostatin, genetic variants</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Endothelin-1 (ET-1)</PrimaryIE>
              <SecondaryIE>amino acid structure of</SecondaryIE>
              <SecondaryIE>axis</SecondaryIE>
              <TertiaryIE>and bone metastases</TertiaryIE>
              <TertiaryIE>and pain</TertiaryIE>
              <SecondaryIE>effects of</SecondaryIE>
              <SecondaryIE>plasma levels</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Endothelin-1 receptors, CRPC</PrimaryIE>
              <SecondaryIE>atrasentan (ABT-627)</SecondaryIE>
              <TertiaryIE>phase III trials in</TertiaryIE>
              <TertiaryIE>phase II trials in</TertiaryIE>
              <TertiaryIE>phase I trials</TertiaryIE>
              <SecondaryIE>
                <Emphasis Type="Italic">EDNRB</Emphasis>
                hypermethylation
              </SecondaryIE>
              <SecondaryIE>expression</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Epothilones, CRPC</PrimaryIE>
              <SecondaryIE>phase I clinical trials of</SecondaryIE>
              <TertiaryIE>ixabepilone</TertiaryIE>
              <TertiaryIE>patupilone</TertiaryIE>
              <SecondaryIE>phase II clinical trials of</SecondaryIE>
              <TertiaryIE>combination studies</TertiaryIE>
              <TertiaryIE>ixabepilone</TertiaryIE>
              <TertiaryIE>patupilone</TertiaryIE>
              <TertiaryIE>toxicity and</TertiaryIE>
              <SecondaryIE>pre-clinical data</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Estramustine</PrimaryIE>
              <SecondaryIE>mechanism of action</SecondaryIE>
              <SecondaryIE>oral bioavailability of</SecondaryIE>
              <SecondaryIE>pharmacodynamic determininants</SecondaryIE>
              <SecondaryIE>pharmacogenetics</SecondaryIE>
              <SecondaryIE>variability, non-genetic sources of</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Estrogens</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Everolimus</PrimaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>F</Heading>
            <IndexEntry>
              <PrimaryIE>Fatty-acid-CoA ligase 3 (FACL3)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Finasteride</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Flutamide</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Food and Drug Administration (FDA), drug approval</PrimaryIE>
              <SecondaryIE>challenges in</SecondaryIE>
              <SecondaryIE>cytotoxic agents</SecondaryIE>
              <TertiaryIE>docetaxel</TertiaryIE>
              <TertiaryIE>estramustine</TertiaryIE>
              <TertiaryIE>mitoxantrone</TertiaryIE>
              <SecondaryIE>efficacy and safety</SecondaryIE>
              <SecondaryIE>hormonal agents</SecondaryIE>
              <SecondaryIE>process</SecondaryIE>
              <SecondaryIE>supportive agents</SecondaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>G</Heading>
            <IndexEntry>
              <PrimaryIE>Gene fusions</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>GM-CSF genes transduced vaccines (GVAX)</PrimaryIE>
              <SecondaryIE>anti-CTLA-4 antibody</SecondaryIE>
              <SecondaryIE>clinical development</SecondaryIE>
              <TertiaryIE>allogeneic cells lines</TertiaryIE>
              <TertiaryIE>oligoclonal antibodies</TertiaryIE>
              <TertiaryIE>T-cell responses</TertiaryIE>
              <TertiaryIE>transduction</TertiaryIE>
              <SecondaryIE>clinical trials</SecondaryIE>
              <TertiaryIE>Phase II-G-9803 and G-0010</TertiaryIE>
              <TertiaryIE>Vital-1</TertiaryIE>
              <TertiaryIE>Vital-2</TertiaryIE>
              <SecondaryIE>contents</SecondaryIE>
              <SecondaryIE>phase I trial</SecondaryIE>
              <SecondaryIE>preclinical developments</SecondaryIE>
              <TertiaryIE>immunogens</TertiaryIE>
              <TertiaryIE>irradiation</TertiaryIE>
              <TertiaryIE>recombinant cytokines</TertiaryIE>
              <TertiaryIE>tumor antigen presentation</TertiaryIE>
              <TertiaryIE>vaccination</TertiaryIE>
              <SecondaryIE>tumor tolerance</SecondaryIE>
              <TertiaryIE>antineoplastic immune response</TertiaryIE>
              <TertiaryIE>B7-H3</TertiaryIE>
              <TertiaryIE>CTLA-4</TertiaryIE>
              <TertiaryIE>indoleamine 2,3 dioxygenase (INDO) expression</TertiaryIE>
              <TertiaryIE>LAG-3</TertiaryIE>
              <TertiaryIE>programmed death 1 (PD1) ligation</TertiaryIE>
              <TertiaryIE>regulatory T-cells (T-regs)</TertiaryIE>
              <SecondaryIE>two dose-escalation studies</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                Gonadotropin releasing hormone (GnRH).
                <Emphasis Type="Italic">See</Emphasis>
                Luteinizing hormone-releasing hormone-I
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Granulocyte stimulating factor (GM-CSF)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                GVAX.
                <Emphasis Type="Italic">See</Emphasis>
                GM-CSF genes transduced vaccines
              </PrimaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>H</Heading>
            <IndexEntry>
              <PrimaryIE>Heat shock protein 27 (Hsp27)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Hedgehog pathways</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Hepatic impairment, mitoxantrone</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Histone deacetylase inhibitors</PrimaryIE>
              <SecondaryIE>romidepsin</SecondaryIE>
              <SecondaryIE>vorinostat</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Hormonal drug development</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Hormonal therapy, platinum agents</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Hsp90 pathway</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>3β-Hydroxysteroid dehydrogenase enzyme</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>17β-Hydroxysteroid dehydrogenase (HSD17) gene</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Hypogonadism</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Hypoxia-inducible factor-1alpha (HIF-1alpha)</PrimaryIE>
              <SecondaryIE>genetic variants of</SecondaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>I</Heading>
            <IndexEntry>
              <PrimaryIE>
                IGF.
                <Emphasis Type="Italic">See</Emphasis>
                Insulin-like growth factor
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Immunohistochemistry (IHC)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Immunomodulators (IMiDs)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Immunotherapy</PrimaryIE>
              <SecondaryIE>androgen-deprivation therapy</SecondaryIE>
              <SecondaryIE>anti-CTLA-4</SecondaryIE>
              <SecondaryIE>antigen presentation enhancement</SecondaryIE>
              <SecondaryIE>combination chemotherapy</SecondaryIE>
              <SecondaryIE>CTLA-4 blockade</SecondaryIE>
              <TertiaryIE>clinical evaluation</TertiaryIE>
              <TertiaryIE>combination therapy</TertiaryIE>
              <TertiaryIE>preclinical models</TertiaryIE>
              <TertiaryIE>regulatory T cells (Tregs)</TertiaryIE>
              <TertiaryIE>T cell activation, mechanism</TertiaryIE>
              <TertiaryIE>toxicity</TertiaryIE>
              <TertiaryIE>vaccination</TertiaryIE>
              <SecondaryIE>docetaxel</SecondaryIE>
              <SecondaryIE>GM-CSF genes transduced vaccines, GVAX</SecondaryIE>
              <TertiaryIE>anti-CTLA-4 antibody</TertiaryIE>
              <TertiaryIE>clinical development</TertiaryIE>
              <TertiaryIE>clinical trials</TertiaryIE>
              <TertiaryIE>preclinical developments</TertiaryIE>
              <TertiaryIE>tumor tolerance</TertiaryIE>
              <SecondaryIE>radiation therapy</SecondaryIE>
              <SecondaryIE>sequential chemotherapy</SecondaryIE>
              <SecondaryIE>sipuleucel-T</SecondaryIE>
              <TertiaryIE>clinical efficacy</TertiaryIE>
              <TertiaryIE>Kaplan–Meier survival benefit</TertiaryIE>
              <TertiaryIE>PA2024, recombinant prostate antigen protein</TertiaryIE>
              <TertiaryIE>safety and tolerability</TertiaryIE>
              <SecondaryIE>tumor-associated antigens</SecondaryIE>
              <SecondaryIE>vaccines</SecondaryIE>
              <TertiaryIE>antigen-presenting cell vaccines</TertiaryIE>
              <TertiaryIE>clinical evaluation</TertiaryIE>
              <TertiaryIE>modalities</TertiaryIE>
              <TertiaryIE>PSA-TRICOM</TertiaryIE>
              <TertiaryIE>regulatory T-cell depletion</TertiaryIE>
              <TertiaryIE>vector-based vaccines</TertiaryIE>
              <TertiaryIE>whole tumor-cell vaccines</TertiaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Inflammation</PrimaryIE>
              <SecondaryIE>causes</SecondaryIE>
              <TertiaryIE>dietary factors</TertiaryIE>
              <TertiaryIE>hormones</TertiaryIE>
              <TertiaryIE>infectious agents</TertiaryIE>
              <TertiaryIE>prostatic and urinary factors</TertiaryIE>
              <SecondaryIE>chronic inflammation</SecondaryIE>
              <TertiaryIE>cyclooxygenase-2</TertiaryIE>
              <TertiaryIE>cytokines and growth factors</TertiaryIE>
              <TertiaryIE>focal prostatic atrophy</TertiaryIE>
              <TertiaryIE>metastasis</TertiaryIE>
              <TertiaryIE>oxidative stress</TertiaryIE>
              <SecondaryIE>genes</SecondaryIE>
              <TertiaryIE>interleukins</TertiaryIE>
              <TertiaryIE>macrophage scavenger receptor (MSR1)</TertiaryIE>
              <TertiaryIE>prostate derived factor (PDF)</TertiaryIE>
              <TertiaryIE>RNASEL</TertiaryIE>
              <TertiaryIE>toll-like receptors (TLRs)</TertiaryIE>
              <SecondaryIE>management, prostate cancer</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Insulin growth factor-binding proteins (IGFBPs)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Insulin-like growth factor (IGF)</PrimaryIE>
              <SecondaryIE>gene expression</SecondaryIE>
              <SecondaryIE>ligands</SecondaryIE>
              <SecondaryIE>pathway</SecondaryIE>
              <SecondaryIE>rational therapeutic targeting of</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Integrins</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Interleukin-6 (IL-6)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Isoenzyme</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Ixabepilone</PrimaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>K</Heading>
            <IndexEntry>
              <PrimaryIE>Kallikrein 2 (KLK2) gene</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Kaplan–Meier survival benefit curve, CRPC</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Ketoconazole</PrimaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>L</Heading>
            <IndexEntry>
              <PrimaryIE>Late-onset hypogonadism (LOH)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Left ventricular ejection fraction (LVEF)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Lenalidomide</PrimaryIE>
              <SecondaryIE>in combination therapy</SecondaryIE>
              <SecondaryIE>as single agent</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Leuprolide</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                LHRH-I.
                <Emphasis Type="Italic">See</Emphasis>
                Luteinizing hormone-releasing hormone-I
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Ligand-binding domain (LBD)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Live vaccines</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Luteinizing hormone-releasing hormone-I (LHRH-I)</PrimaryIE>
              <SecondaryIE>agonists</SecondaryIE>
              <TertiaryIE>principles, oncological and gynecological use</TertiaryIE>
              <TertiaryIE>prostate cancer therapy</TertiaryIE>
              <TertiaryIE>sustained delivery systems</TertiaryIE>
              <SecondaryIE>amino acid sequence of</SecondaryIE>
              <SecondaryIE>antagonistic analogs</SecondaryIE>
              <TertiaryIE>clinical applications</TertiaryIE>
              <TertiaryIE>clinical findings</TertiaryIE>
              <TertiaryIE>cytotoxic analogs, in prostate cancer</TertiaryIE>
              <TertiaryIE>development</TertiaryIE>
              <TertiaryIE>direct effects on tumors</TertiaryIE>
              <TertiaryIE>edematogenic effect</TertiaryIE>
              <TertiaryIE>gynecological and oncological use, effects on pituitary receptors</TertiaryIE>
              <TertiaryIE>mechanism of action</TertiaryIE>
              <TertiaryIE>receptors for LHRH type I on tumors</TertiaryIE>
              <TertiaryIE>side effects</TertiaryIE>
              <TertiaryIE>targeted cytotoxic</TertiaryIE>
              <TertiaryIE>use in benign prostatic hyperplasia (BPH)</TertiaryIE>
              <TertiaryIE>use in prostate cancer</TertiaryIE>
              <SecondaryIE>role</SecondaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>M</Heading>
            <IndexEntry>
              <PrimaryIE>Mammalian target of rapamycin (mTOR) inhibition</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Mass spectrometry (MS)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Matrix-assisted laser desorption ionization (MALDI)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Matrix metalloproteinases (MMPs)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Metalloproteinase-1 (MMP1)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>2-Methoxyestradiol (2-ME)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Methylseleninic acid (MSA)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Microtubule targeting agents</PrimaryIE>
              <SecondaryIE>castrate resistant prostate cancer</SecondaryIE>
              <TertiaryIE>definition</TertiaryIE>
              <TertiaryIE>docetaxel</TertiaryIE>
              <TertiaryIE>epothilones in</TertiaryIE>
              <SecondaryIE>cytoskeleton of</SecondaryIE>
              <TertiaryIE>dynamic instability</TertiaryIE>
              <TertiaryIE>microtubule-associated proteins (MAPs)</TertiaryIE>
              <TertiaryIE>polymerization</TertiaryIE>
              <TertiaryIE>protofilaments</TertiaryIE>
              <SecondaryIE>depolymerizing agents</SecondaryIE>
              <TertiaryIE>colchicine class</TertiaryIE>
              <TertiaryIE>combretastatin A-4</TertiaryIE>
              <TertiaryIE>definition of</TertiaryIE>
              <TertiaryIE>dolastatin peptides</TertiaryIE>
              <TertiaryIE>2-methoxyestradiol (2-ME)</TertiaryIE>
              <TertiaryIE>mivobulin isethionate</TertiaryIE>
              <TertiaryIE>peptides and depsipeptides</TertiaryIE>
              <TertiaryIE>vinca alkaloids</TertiaryIE>
              <SecondaryIE>drug sensitivity in</SecondaryIE>
              <TertiaryIE>cells lines selection</TertiaryIE>
              <TertiaryIE>dynamics</TertiaryIE>
              <TertiaryIE>intrinsic sensitivity</TertiaryIE>
              <SecondaryIE>non-taxane drugs</SecondaryIE>
              <SecondaryIE>paclitaxel</SecondaryIE>
              <TertiaryIE>interaction of</TertiaryIE>
              <TertiaryIE>mechanism of</TertiaryIE>
              <SecondaryIE>resistance to</SecondaryIE>
              <SecondaryIE>XRP6258</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Microvessel density (MVD) and VEGF</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Mitoxantrone</PrimaryIE>
              <SecondaryIE>castration resistant prostate cancer</SecondaryIE>
              <SecondaryIE>development</SecondaryIE>
              <SecondaryIE>dosing and administration</SecondaryIE>
              <SecondaryIE>drug distribution</SecondaryIE>
              <SecondaryIE>efficacy</SecondaryIE>
              <SecondaryIE>mechanism of action</SecondaryIE>
              <SecondaryIE>and pharmacodynamic determininants</SecondaryIE>
              <SecondaryIE>pharmacogenetics</SecondaryIE>
              <SecondaryIE>pharmacokinetics</SecondaryIE>
              <SecondaryIE>pharmacological considerations</SecondaryIE>
              <SecondaryIE>safety and precautions</SecondaryIE>
              <TertiaryIE>adverse reactions</TertiaryIE>
              <TertiaryIE>black-box warnings</TertiaryIE>
              <TertiaryIE>pregnancy</TertiaryIE>
              <SecondaryIE>therapy</SecondaryIE>
              <TertiaryIE>castration resistant prostate cancer (CRPC)</TertiaryIE>
              <TertiaryIE>docetaxel and estramustine</TertiaryIE>
              <TertiaryIE>
                mitoxantrone
                <Emphasis Type="Italic">vs</Emphasis>
                .docetaxel
              </TertiaryIE>
              <SecondaryIE>variability, non-genetic sources of</SecondaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>N</Heading>
            <IndexEntry>
              <PrimaryIE>Neuroendocrine differentiation (NE), platinum agents</PrimaryIE>
              <SecondaryIE>androgen-independent subpopulation</SecondaryIE>
              <SecondaryIE>chromogranin A (CgA)</SecondaryIE>
              <SecondaryIE>hormonal therapy</SecondaryIE>
              <SecondaryIE>
                <Emphasis Type="Italic">in vitro</Emphasis>
                and
                <Emphasis Type="Italic">in vivo</Emphasis>
                assays
              </SecondaryIE>
              <SecondaryIE>LNCaP cells</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Nilutamide</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                Non-steroidal anti-inflammatory agents
                <Emphasis Type="Bold">(</Emphasis>
                NSAIDs)
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Nonsteroidal AR antagonists</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>N-terminal domain (NTD)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Nuclear receptor coregulators</PrimaryIE>
              <SecondaryIE>androgen receptor</SecondaryIE>
              <TertiaryIE>basic mechanism</TertiaryIE>
              <TertiaryIE>structure and function</TertiaryIE>
              <TertiaryIE>synthesis and metabolites</TertiaryIE>
              <TertiaryIE>therapeutic potential, signaling pathways</TertiaryIE>
              <SecondaryIE>clinical relevance and therapeutic potential in CaP</SecondaryIE>
              <TertiaryIE>AR-associated coregulators</TertiaryIE>
              <TertiaryIE>coregulator expression</TertiaryIE>
              <SecondaryIE>targeting coregulator activity</SecondaryIE>
              <SecondaryIE>targeting coregulator expression</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Nuclear transcription factor (NFκB)</PrimaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>O</Heading>
            <IndexEntry>
              <PrimaryIE>OATP1B3, organic anion transporter</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Office of Oncology Drug Products (OODP)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Omega-3 fatty acids</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Oncogene beta-catenin</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Oncologic Drugs Advisory Committee (ODAC)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>ONY-P1</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Orchiectomy</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                Osteoblastic bone metastases.
                <Emphasis Type="Italic">See also</Emphasis>
                Bone metastases
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Osteoclastic bone metastases</PrimaryIE>
              <SecondaryIE>interleukin-6 (IL-6)</SecondaryIE>
              <SecondaryIE>matrix metalloproteinases (MMPs)</SecondaryIE>
              <SecondaryIE>PTHrP protein</SecondaryIE>
              <SecondaryIE>RANKL and OPG</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Osteoclastic bone resorption</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                Osteoclastogenesis inhibitory factor (OCIF).
                <Emphasis Type="Italic">See</Emphasis>
                Osteoprotegerin (OPG)
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Osteonecrosis of jaw (ONJ)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Osteoprotegerin (OPG)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Oxaliplatin</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Oxidative stress, chronic inflammation</PrimaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>P</Heading>
            <IndexEntry>
              <PrimaryIE>p53</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Paclitaxel</PrimaryIE>
              <SecondaryIE>interaction of</SecondaryIE>
              <SecondaryIE>mechanism of</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Pain, endothelin-1 (ET-1)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Parathyroid hormone-related protein (PTHrP)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Patupilone</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                PDGF.
                <Emphasis Type="Italic">See</Emphasis>
                Platelet-derived growth factor
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Pharmacogenetics</PrimaryIE>
              <SecondaryIE>angiogenesis</SecondaryIE>
              <TertiaryIE>endostatin gene</TertiaryIE>
              <TertiaryIE>HIF-1α gene</TertiaryIE>
              <TertiaryIE>metalloproteinase-1 (MMP1) gene</TertiaryIE>
              <TertiaryIE>PDGF and PDGFR gene</TertiaryIE>
              <TertiaryIE>tumor necrosis factor (TNF) gene</TertiaryIE>
              <TertiaryIE>VEGF gene</TertiaryIE>
              <SecondaryIE>5α-reductase inhibitors</SecondaryIE>
              <SecondaryIE>docetaxel</SecondaryIE>
              <SecondaryIE>estramustine</SecondaryIE>
              <SecondaryIE>human CaP and LNCaP cell lines</SecondaryIE>
              <SecondaryIE>mitoxantrone</SecondaryIE>
              <SecondaryIE>
                <Emphasis Type="Italic">SLCO1B3</Emphasis>
                gene
              </SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Pharmacology</PrimaryIE>
              <SecondaryIE>docetaxel</SecondaryIE>
              <SecondaryIE>estramustine</SecondaryIE>
              <SecondaryIE>mitoxantrone</SecondaryIE>
              <SecondaryIE>satraplatin</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Phosphatase and tensin homologue (PTEN)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Phosphatidylinositol 3-kinase (PI3K)-signaling</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Picoplatin</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>PI3 kinase/Akt pathways</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Pituitary LHRH receptors</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Platelet-derived growth factor (PDGF)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Platelet-derived growth factor receptor (PDGFR)</PrimaryIE>
              <SecondaryIE>bone tropism of</SecondaryIE>
              <SecondaryIE>patient selection</SecondaryIE>
              <SecondaryIE>PC-3MM2-MDR cells</SecondaryIE>
              <SecondaryIE>and VEGF</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Platinum agents</PrimaryIE>
              <SecondaryIE>cisplatin and carboplatin, first-line chemotherapy</SecondaryIE>
              <TertiaryIE>multiagent regimens</TertiaryIE>
              <TertiaryIE>single-agent</TertiaryIE>
              <SecondaryIE>neuroendocrine differentiation (NE) in</SecondaryIE>
              <TertiaryIE>androgen-independent subpopulation</TertiaryIE>
              <TertiaryIE>chromogranin A (CgA)</TertiaryIE>
              <TertiaryIE>hormonal therapy</TertiaryIE>
              <TertiaryIE>
                <Emphasis Type="Italic">in vitro</Emphasis>
                and
                <Emphasis Type="Italic">in vivo</Emphasis>
                assays
              </TertiaryIE>
              <TertiaryIE>LNCaP cells</TertiaryIE>
              <SecondaryIE>oxaliplatin</SecondaryIE>
              <SecondaryIE>picoplatin</SecondaryIE>
              <SecondaryIE>second-line therapy</SecondaryIE>
              <TertiaryIE>carboplatin</TertiaryIE>
              <TertiaryIE>satraplatin and prednisone</TertiaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Progestins</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Prostate cancer prevention trial (PCPT)</PrimaryIE>
              <SecondaryIE>adverse events</SecondaryIE>
              <SecondaryIE>finasteride evaluation</SecondaryIE>
              <SecondaryIE>steroids</SecondaryIE>
              <SecondaryIE>tumor grade assessment</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Prostatectomy</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Prostate specific antigen (PSA)</PrimaryIE>
              <SecondaryIE>blood-based biomarker</SecondaryIE>
              <SecondaryIE>clinical trial endpoint</SecondaryIE>
              <TertiaryIE>limitations</TertiaryIE>
              <TertiaryIE>progression</TertiaryIE>
              <TertiaryIE>response</TertiaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Proteomics applications</PrimaryIE>
              <SecondaryIE>blood-based protein biomarkers</SecondaryIE>
              <SecondaryIE>cancer biomarkers</SecondaryIE>
              <SecondaryIE>SELDI-TOF</SecondaryIE>
              <SecondaryIE>tissue-based protein biomarkers</SecondaryIE>
              <TertiaryIE>diagnostic</TertiaryIE>
              <TertiaryIE>prognostic</TertiaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>R</Heading>
            <IndexEntry>
              <PrimaryIE>Radiation therapy</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Radical prostatectomy</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Radiopharmaceuticals</PrimaryIE>
              <SecondaryIE>chemotherapy and</SecondaryIE>
              <TertiaryIE>doxorubicin</TertiaryIE>
              <TertiaryIE>
                <Superscript>153</Superscript>
                Sm-EDTMP and docetaxel
              </TertiaryIE>
              <TertiaryIE>
                <Superscript>89</Superscript>
                Sr and cisplatin
              </TertiaryIE>
              <SecondaryIE>comparison trials</SecondaryIE>
              <SecondaryIE>guidelines for</SecondaryIE>
              <SecondaryIE>indications and contraindications for</SecondaryIE>
              <SecondaryIE>physical properties and mechanisms of</SecondaryIE>
              <SecondaryIE>
                <Superscript>223</Superscript>
                radium
              </SecondaryIE>
              <TertiaryIE>bone-metastatic CRPC patients</TertiaryIE>
              <TertiaryIE>phase I clinical trial</TertiaryIE>
              <TertiaryIE>phase II clinical trial</TertiaryIE>
              <TertiaryIE>phase III trials</TertiaryIE>
              <SecondaryIE>
                <Superscript>153</Superscript>
                samarium-EDTMP
              </SecondaryIE>
              <TertiaryIE>pain scores in</TertiaryIE>
              <TertiaryIE>placebo-controlled randomized trials in</TertiaryIE>
              <TertiaryIE>repetitive doses of</TertiaryIE>
              <SecondaryIE>
                <Superscript>89</Superscript>
                strontium
              </SecondaryIE>
              <TertiaryIE>pain in</TertiaryIE>
              <TertiaryIE>randomized trial in</TertiaryIE>
              <TertiaryIE>repeated doses of</TertiaryIE>
              <SecondaryIE>uses of</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                <Superscript>223</Superscript>
                Radium
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Receptor activator of NF-κB (RANK)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Receptor activator of nuclear factor kappa B ligand (RANKL)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Reduction by Dutasteride of Prostate Cancer Events Trial (REDUCE)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Renal failure, bisphosphonates</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Renal impairment, mitoxantrone</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Retinoid receptor ligands</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Romidepsin</PrimaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>S</Heading>
            <IndexEntry>
              <PrimaryIE>
                <Superscript>153</Superscript>
                Samarium-EDTMP
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Satraplatin</PrimaryIE>
              <SecondaryIE>JM118</SecondaryIE>
              <SecondaryIE>mechanism of action</SecondaryIE>
              <SecondaryIE>variability, non-genetic sources of</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Selective reaction monitoring (SRM)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Selenium and Vitamin E Cancer Prevention Trial (SELECT)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Selenium, dietary risk factor</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                <Emphasis Type="Italic">Serenoa repens</Emphasis>
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Signal transduction pathways</PrimaryIE>
              <SecondaryIE>IGF and IGF-1R</SecondaryIE>
              <SecondaryIE>IGFBPs and CRPC</SecondaryIE>
              <SecondaryIE>PI3K-mediated survival signaling</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Single nucleotide polymorphisms (SNPs)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Sipuleucel-T vaccine, CRPC</PrimaryIE>
              <SecondaryIE>clinical efficacy</SecondaryIE>
              <TertiaryIE>D9902A study</TertiaryIE>
              <TertiaryIE>developmental history</TertiaryIE>
              <TertiaryIE>D9901 study</TertiaryIE>
              <TertiaryIE>phase III clinical studies</TertiaryIE>
              <TertiaryIE>phase I/II studies</TertiaryIE>
              <SecondaryIE>Kaplan–Meier survival benefit</SecondaryIE>
              <SecondaryIE>metastatic</SecondaryIE>
              <SecondaryIE>nonmetastatic</SecondaryIE>
              <SecondaryIE>PA2024, recombinant prostate antigen protein</SecondaryIE>
              <SecondaryIE>safety and tolerability</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Skeletal-related event (SRE)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                Solute carrier organic anion transporter 1B3 (
                <Emphasis Type="Italic">SLCO1B3</Emphasis>
                ) gene
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Somatic 5-alpha reductase mutations</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Sorafenib</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Southwestern Oncology Group Intergroup protocol 99-16 (SWOG 99-16)</PrimaryIE>
              <SecondaryIE>clinical implications</SecondaryIE>
              <SecondaryIE>
                docetaxel-estramustine (DE)
                <Emphasis Type="Italic">vs</Emphasis>
                . mitoxantrone-prednisone (MP)
              </SecondaryIE>
              <SecondaryIE>quality of life and pain scores</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>SRC-1</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Steroid 5α-reductase (SRD5A)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Steroids</PrimaryIE>
              <SecondaryIE>AR antagonists</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Stroma-derived factor (SDF-1/CXCL12)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                <Superscript>89</Superscript>
                Strontium
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Sunitinib</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Surface-enhanced laser desorption ionization time-of-flight (SELDI-TOF)</PrimaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>T</Heading>
            <IndexEntry>
              <PrimaryIE>TAK-700, CYP17 inhibitor</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Tamoxifen</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Tandutinib</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Targeted cytotoxic analog therapy</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>TAX 327</PrimaryIE>
              <SecondaryIE>clinical implications</SecondaryIE>
              <SecondaryIE>discrepancies</SecondaryIE>
              <SecondaryIE>follow-up survival analysis</SecondaryIE>
              <SecondaryIE>neutropenia</SecondaryIE>
              <SecondaryIE>pain reduction and quality of life</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Taxane</PrimaryIE>
              <SecondaryIE>chemotherapy</SecondaryIE>
              <SecondaryIE>combination therapy</SecondaryIE>
              <TertiaryIE>anti-angiogenesis agents</TertiaryIE>
              <TertiaryIE>bone targeted therapies</TertiaryIE>
              <TertiaryIE>calcitriol combination therapy</TertiaryIE>
              <TertiaryIE>vaccine-taxane therapy</TertiaryIE>
              <SecondaryIE>cytotoxicity</SecondaryIE>
              <SecondaryIE>docetaxel with estramustine</SecondaryIE>
              <SecondaryIE>paclitaxel</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                Taxol
                <Superscript>®</Superscript>
                .
                <Emphasis Type="Italic">See</Emphasis>
                Paclitaxel
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                Taxotere
                <Superscript>®</Superscript>
                .
                <Emphasis Type="Italic">See</Emphasis>
                Docetaxel
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Testosterone</PrimaryIE>
              <SecondaryIE>conversion to dihydrotestosterone</SecondaryIE>
              <SecondaryIE>deficiency</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Testosterone replacement therapy (TRT)</PrimaryIE>
              <SecondaryIE>follow up for prostate cancer</SecondaryIE>
              <SecondaryIE>risk of prostate cancer</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Thalidomide</PrimaryIE>
              <SecondaryIE>analogs</SecondaryIE>
              <SecondaryIE>in combination therapy</SecondaryIE>
              <TertiaryIE>bevacizumab and prednisone</TertiaryIE>
              <TertiaryIE>cyclophosphamide</TertiaryIE>
              <TertiaryIE>dexamethasone</TertiaryIE>
              <TertiaryIE>docetaxel</TertiaryIE>
              <TertiaryIE>estramustine</TertiaryIE>
              <TertiaryIE>granulocyte stimulating factor (GM-CSF)</TertiaryIE>
              <TertiaryIE>paclitaxel</TertiaryIE>
              <TertiaryIE>trials in</TertiaryIE>
              <SecondaryIE>lenalidomide</SecondaryIE>
              <TertiaryIE>in combination therapy</TertiaryIE>
              <TertiaryIE>as single agent</TertiaryIE>
              <SecondaryIE>as single agent</SecondaryIE>
              <TertiaryIE>
                phase III study
                <Emphasis Type="Italic">vs</Emphasis>
                . placebo
              </TertiaryIE>
              <TertiaryIE>phase II study of</TertiaryIE>
              <TertiaryIE>trials in</TertiaryIE>
              <TertiaryIE>tumor microenvironment</TertiaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>TIF-2 overexpression</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Tissue-based protein biomarkers</PrimaryIE>
              <SecondaryIE>diagnostic</SecondaryIE>
              <SecondaryIE>prognostic</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>TOK-001</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Toll-like receptors (TLRs), inflammation</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Transcriptional-coactivating protein</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Transcriptional corepressors</PrimaryIE>
              <SecondaryIE>
                <Emphasis Type="Italic">vs</Emphasis>
                . coactivator proteins
              </SecondaryIE>
              <SecondaryIE>role in AR antagonist action</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>
                TRT.
                <Emphasis Type="Italic">See</Emphasis>
                Testosterone replacement therapy
              </PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Tumor necrosis factor (TNF)</PrimaryIE>
              <SecondaryIE>TNF-α</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Tyrosine kinases</PrimaryIE>
              <SecondaryIE>AZD2171 (cediranib)</SecondaryIE>
              <SecondaryIE>sorafenib</SecondaryIE>
              <SecondaryIE>sunitinib</SecondaryIE>
              <SecondaryIE>tandutinib</SecondaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>V</Heading>
            <IndexEntry>
              <PrimaryIE>Vaccines</PrimaryIE>
              <SecondaryIE>antigen-presenting cell vaccines</SecondaryIE>
              <SecondaryIE>clinical evaluation</SecondaryIE>
              <SecondaryIE>GM-CSF genes transduced vaccines, GVAX</SecondaryIE>
              <TertiaryIE>anti-CTLA-4 antibody</TertiaryIE>
              <TertiaryIE>clinical development</TertiaryIE>
              <TertiaryIE>clinical trials</TertiaryIE>
              <TertiaryIE>preclinical developments</TertiaryIE>
              <TertiaryIE>tumor tolerance</TertiaryIE>
              <SecondaryIE>live</SecondaryIE>
              <SecondaryIE>modalities</SecondaryIE>
              <SecondaryIE>PSA-TRICOM</SecondaryIE>
              <SecondaryIE>regulatory T-cell depletion</SecondaryIE>
              <SecondaryIE>vector-based vaccines</SecondaryIE>
              <SecondaryIE>whole tumor-cell vaccines</SecondaryIE>
              <TertiaryIE>GVAX</TertiaryIE>
              <TertiaryIE>ONY-P1</TertiaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Vaccine-taxane therapy</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Vascular endothelial growth factor (VEGF)</PrimaryIE>
              <SecondaryIE>angiogenesis inhibitors</SecondaryIE>
              <SecondaryIE>angiogenesis regulation</SecondaryIE>
              <SecondaryIE>genetic variants of</SecondaryIE>
              <TertiaryIE>gene–gene interaction</TertiaryIE>
              <TertiaryIE>haplotype</TertiaryIE>
              <TertiaryIE>polymorphisms</TertiaryIE>
              <TertiaryIE>thrombospondin-1 (TSP1)</TertiaryIE>
              <SecondaryIE>targeted inhibition</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Vinca alkaloids</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Visual analog scale (VAS)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Vitamin D</PrimaryIE>
              <SecondaryIE>antineoplastic activity</SecondaryIE>
              <TertiaryIE>angiogenesis and invasiveness</TertiaryIE>
              <TertiaryIE>apoptosis</TertiaryIE>
              <TertiaryIE>proliferation</TertiaryIE>
              <TertiaryIE>signaling</TertiaryIE>
              <TertiaryIE>spectrum of activity</TertiaryIE>
              <SecondaryIE>calcitriol and</SecondaryIE>
              <TertiaryIE>analogs</TertiaryIE>
              <TertiaryIE>cytotoxic chemotherapy</TertiaryIE>
              <TertiaryIE>phase II studies</TertiaryIE>
              <TertiaryIE>phase I studies</TertiaryIE>
              <TertiaryIE>steroids</TertiaryIE>
              <SecondaryIE>epidemiology of</SecondaryIE>
              <TertiaryIE>dairy product consumption</TertiaryIE>
              <TertiaryIE>outcomes</TertiaryIE>
              <TertiaryIE>solar UV radiation</TertiaryIE>
              <TertiaryIE>vitamin D receptor (VDR)</TertiaryIE>
              <SecondaryIE>NSAIDs</SecondaryIE>
              <SecondaryIE>radiation</SecondaryIE>
              <SecondaryIE>retinoid receptor ligands</SecondaryIE>
              <SecondaryIE>tamoxifen</SecondaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Vitamin D receptor (VDR)</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Vitamin E</PrimaryIE>
            </IndexEntry>
            <IndexEntry>
              <PrimaryIE>Vorinostat</PrimaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>W</Heading>
            <IndexEntry>
              <PrimaryIE>World Cancer Research Fund and American Institute for Cancer Research (WCRF–AICR) report</PrimaryIE>
            </IndexEntry>
          </IndexDiv>
          <IndexDiv>
            <Heading>Z</Heading>
            <IndexEntry>
              <PrimaryIE>Zoledronic acid</PrimaryIE>
            </IndexEntry>
          </IndexDiv>
        </Index>
      </BodyBackmatter>
      <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_BookBackMatter.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
    </BookBackmatter>
  </Book>
</Publisher>
